Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 77-88

  Pallis, M ^a   Turzanski, J ^a   Langabeer, S ^b   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

AML; Daunorubicin; MDR; Standardised flow cytometry

Indexed keywords

ABC TRANSPORTER; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; BLOOD; BONE MARROW CELL; DRUG EFFECT; FLOW CYTOMETRY; GENE; GENETICS; HUMAN; METHODOLOGY; MULTIDRUG RESISTANCE; PATHOLOGY; REPRODUCIBILITY;

ATP-BINDING CASSETTE TRANSPORTERS; BLAST CRISIS; BONE MARROW CELLS; CYCLOSPORINE; CYCLOSPORINS; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; GENES, MDR; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; REPRODUCIBILITY OF RESULTS;

EID: 0032620223     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_10     Document Type: Article

References (19)

1. Izquierdo MA, Scheffer GL, Flens MJ, Schroieijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-mediated multidrug resistance. Eur J Cancer 1996;32A:979-984.
2. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-957.
3. Marie J-P. P-glycoprotein in adult hematological malignancies. Hematology/Oncology Clinics of N America 1995;9:239-249.
4. Sonneveld P. Multidrug resistance in acute myeloid leukaemia. Balliere's Clinical Haematology 1996;9:185-203.
5. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid-leukemia. Blood 1996;87(6):2464-2469.
6. Xu D, Knaust E, Pisa P, Palucka K, Lundenberg J, Arestrom I, Peterson C, Gruber A. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Br J Haematol 1996;92:847-854.
7. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A south-west oncology group study. Blood 1997;89(9):3323-3329.
8. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M. P-glycoprotein (pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997;96:356-365.
9. Sonneveld P. Reversal of multidrug-resistance in acute myeloid-leukemia and other hematological malignancies. European Journal Of Cancer 1996;32A(6): 1062-1069.
10. Estey E, Thall PF, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller CA, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M. Use of Granulocyte Colony-Stimulating Factor Before, During and After Fludarabine Plus Cytarabine Induction Therapy of Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndromes: Comparison with Fludarabine plus Cytarabine Without Granulocyte Colony-Stimulating Factor. J Clin Oncol 1994;12:671-678.
11. Beck WT, Grogan TM, Willman CL, Cordoncardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect p-glycoprotein-associated multidrug-resistance in patients' tumors -consensus recommendations. Cancer Research 1996; 56(13):3010-3020.
12. Sonneveld P, van den Engh GJ. Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cells determined by flow cytometry. Leukemia Research 1981;5:251-257.
13. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumor samples for p-glycoprotein and multidrug resistance-associated protein. European Journal Of Cancer 1996;32A(6):1024-1033.
14. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele G, Wahrer DCR, Eckman CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B, Schuurhuis GJ. Quality Control of multidrug resistance assays in adult acute leukaemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996:87:4809-4816.
15. Pallis M, Russell NH. Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. British Journal Of Haematology 1998;100(1):194-197.
16. te Boekhorst PAW, Lowenberg B, Vankapel J, Nooter K, Sonneveld P. Multidrug-resistant cells with high proliferative capacity determine response to therapy in acute myeloid-leukemia. Leukemia 1995; 9(6): 1025-1031.
17. Perrot JY, Faussat AM, Zhou DC, Zittoun R, Robert J, Marie JP. Evaluation multicentrique du phenotype MDR dans Ies leucemies: analyse intermediare de l'experience francaise. Bulletin Du Cancer 1996;83(8):634-640.
18. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR-1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 1995:86:2329-2342.
19. Sincock PM, Ashman LK. Expression of c-kit and functional drug efflux are correlated in de novo acute myeloid leukaemia. Leukemia 1997;11:1850-1857.